IL6 and infection: Potential exclusion criteria of future clinical trials may be derived from the known clinical side effect profile of IL-6 inhibitors, e.g., patients with certain infections, active tuberculosis or malignancies, abnormal blood cell counts, and high risk of gastrointestinal perforation.